MedCity – Insulin startup Thermalin gets JDRF support for an ultra rapid-acting insulin for T1D

Cleveland-based Thermalin said today that JDRF will provide it with up to $1 million for specific milestones related to identifying a clinical candidate insulin analog with a shorter tail of action.

Read more

Posted in Drugs Glucose & Insulin